Leap Investments’s Moderna MRNA Stock Holding History

Leap Investments’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-34,400	Closed	-$504K	–	452
2019 Q2	$504K	Buy	+34,400	New	+$739K	0.68%	42

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Leap Investments's MRNA Position: Q3 2019 in Review

Leap Investments sold out of Moderna (MRNA) in Q3 2019, closing a stake of 34,400 shares — an estimated $504K sold.

Leap Investments first reported a position in MRNA in Q2 2019 and held it in 1 quarter. The position peaked at $504K in Q2 2019. 136 funds tracked by Wall St. Rank hold MRNA as of Q3 2019.

Leap Investments reported no remaining Moderna position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 34,400 Moderna shares in Q3 2019, an estimated $504K.
Leap Investments first reported a position in Moderna in Q2 2019 and held it in 1 quarter.
Leap Investments's Moderna position peaked at $504K in Q2 2019.
136 funds tracked by Wall St. Rank held Moderna as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.